Effectiveness of pneumococcal polysaccharide vaccine in older adults.

By L. Jackson, K. Neuzil, Onchee Yu, P. Benson, W. Barlow, A. Adams, C. A. Hanson, Lisa D. Mahoney, D. Shay, W. Thompson. New England Journal of Medicine, 2003

631 citations recorded by the source corpus.

Subfields: Epidemiology

View Paper: https://www.semanticscholar.org/paper/b069c73cf56a8f2bc1cbb1dec939b1b6930bdd66

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Guidelines for the management of adult lower respiratory tract infections - Full version (2011, neutral): “In contrast, some other cohort studies have found no protection against all-cause pneumonia or hospitalization for pneumonia [543,550].”
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “The overall effectiveness against invasive pneumococcal disease among persons 65 years of age is 44%–75% [306, 308, 310], although efficacy may decrease with advancing age [308].”
Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults (2003, background): “Postlicensure epidemiological studies, including a recent large observational study, involving elderly persons and younger adults with certain chronic medical conditions have documented effectiveness of pneumococcal polysaccharide vaccines for prevention of invasive infection (bacteremia and meningi”
Measuring diagnoses: ICD code accuracy. (2005, background): “…of complications, track utilization rates, and determine the case fatality and morbidity rates (see Calle et al. 2003 for a recent example) (Steinman, Landefeld, and Gonzales 2000; Calle et al. 2003; Charbonneau et al. 2003; Jackson et al. 2003; Martin et al. 2003; Studdert and Gresenz 2003).”
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “Pneumococcal polysaccharide vaccine is recommended for patients with COPD who are 65 years and older (141, 142).”